[ad_1]
A Coronavac vaccine it is safe and has the ability to produce an immune response in the body 28 days after its application in 97% of cases. The information was published Tuesday night in the Lancet Infectious Diseases. The results of this study have been reviewed by several scientists.
The immunizer is being developed by the Chinese pharmaceutical company Sinovac in partnership with Butantã Institute. The third and final phase of the trial involves 13,000 health professionals in 16 research centers in São Paulo, Rio de Janeiro, Minas Gerais, Rio Grande do Sul, Paraná, Mato Grosso, Mato Grosso do Sul and the Federal District. To date, more than 10,000 people have received at least one of the two doses of the vaccine or the placebo.
In an interview with a Pernambuco radio station, the governor of São Paulo, João Doria (PSDB), also reported this Tuesday that the The Butantã Institute should receive the first batch of Coronavac next Thursday, 19, a day ahead of schedule. About 120 thousand doses should reach São Paulo on the date.
Last week, Anvisa authorized the resumption of Coronavac clinical trials. The study had been suspended on Monday the 9th due to the occurrence of a serious adverse event in one of the volunteers. According to sources in the investigation, the fact was the death of a 32-year-old man, with suicide as the probable cause, and that it would have nothing to do with the immunizer.
In Brazil, the Butantã Institute says it is close to announcing CoronaVac national studies with the elderly and children. The protocol for the third stage of clinical trials in the country, published in an international journal, provides for the immunization of more than 1,200 volunteers over 60 years of age.
[ad_2]
